Treatment
CAR-T cells clinical trials
We’re tracking 534 recruiting studies that include CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07266181RecruitingPhase 1
CAR-T cell therapy for tough-to-treat membranous nephropathy
This trial tests whether specially engineered immune cells (CAR-T cells) can help people with a kidney condition called primary membranous nephropathy that has not improved with standard treatments. The goal is to see if this therapy can reduce protein in the urine and protect kidney function.
Xi'an, ChinaAges 18 years+ - NCT07318259RecruitingPhase 1
Study of a new CAR-T therapy for lupus
This trial tests a fast-acting CAR-T therapy that targets BCMA and CD70 proteins to treat lupus. It may help people with moderate-to-severe lupus that hasn't improved with standard treatments.
Nanjing, JiangsuAges 18 years+ - NCT07331467RecruitingPhase 1
Ultra-fast CAR-T cell therapy for lupus
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
Nanjing, JiangsuAges 18 years+ - NCT07339332RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Wuhan, HubeiAges 18–65 - NCT07478848RecruitingPhase 1
Radiation, Vancomycin, and CAR-T for B-cell lymphoma
This trial tests whether giving radiation and an oral antibiotic (vancomycin) before CAR-T therapy helps treat B-cell lymphoma more effectively. It is for people who are already scheduled to receive CAR-T treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT07369492RecruitingPhase 1
Study of BAFF-R CAR-T cells for CD19-negative B-cell lymphoma
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
SuzhouAges 18 years+ - NCT03375619Recruiting
Long-term follow-up after CAR-T treatment
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
Milwaukee, WisconsinAges 18–80 - NCT07489534RecruitingPhase 2
CAR-T therapy for multiple myeloma with kidney problems
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT07509086RecruitingPhase 2
Enhanced CAR-T therapy for relapsed multiple myeloma
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
Changchun, JilinAges 18–80 - NCT07519187RecruitingEarly Phase 1
CAR-T Cell Therapy for Hard-to-Treat Blood Cancers
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
Chengdu, ChengduAges 18–75 - NCT07523529RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Shenzhen, GuangdongAges 18–75 - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07528105RecruitingEarly Phase 1
CAR-T Cell Therapy for Early-Stage Type 1 Diabetes
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
ShanghaiAges 18–40 - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65 - NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07587840RecruitingPhase 2
CAR-T Cell Therapy After Initial Treatment for Follicular Lymphoma
This study tests a new type of immunotherapy called CAR-T cells (designed cells that fight lymphoma) given after you've received standard chemotherapy for follicular lymphoma. The goal is to help prevent the cancer from coming back or growing, especially if your cancer didn't fully disappear or you have high-risk features.
Beijing, Beijing MunicipalityAges 18–85 - NCT07668557RecruitingPhase 1
CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Nanchang, JiangxiAges 18–70 - NCT05477927RecruitingPhase 1
CAR-T therapy for cancers spread to lining of lungs, belly, or brain
This trial tests an experimental CAR-T cell treatment that targets proteins on cancer cells that have spread to the lining of the lungs, belly, or brain. It may help people whose cancer has not responded to standard treatments.
Chengdu, SichuanAges 18–80 - NCT06006741RecruitingPhase 1
CAR-T cell therapy for multiple myeloma patients
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
Shenzhen, GuangdongAges 18–80 - NCT06560827RecruitingPhase 1
CAR-T Cells for Liver Cancer After Surgery
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
BeijingAges 18–75 - NCT05432882RecruitingPhase 1/Phase 2
CD19/22 CAR-T for certain B-cell blood cancers
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
Shenzhen, GuangdongAges 6 months–75 years
Common questions
- Are there clinical trials studying CAR-T cells?
- Yes. Clin2 currently lists 534 recruiting studies that include CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.